Published in Gut on March 23, 2017
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A (2009) 6.91
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology (2014) 4.98
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology (2011) 4.06
Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 3.64
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol (2014) 3.43
Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov (2005) 3.23
Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol (2012) 3.15
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med (2005) 2.73
Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology (2013) 2.72
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet (2010) 2.68
The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest (2012) 2.65
'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf (2006) 2.50
Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther (2011) 2.50
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology (2015) 2.43
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Outcome and prognostic markers in severe drug-induced liver disease. Hepatology (2005) 2.36
Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci (2013) 2.34
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology (2013) 2.24
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J (2007) 2.17
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology (2013) 2.02
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol (2010) 1.97
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol (2011) 1.65
Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res (2013) 1.62
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol (2011) 1.60
Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci (2007) 1.52
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother (2007) 1.47
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology (2000) 1.46
RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci (2015) 1.45
FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today (2011) 1.42
Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol (2011) 1.40
Pharmacogenetics of drug-induced liver injury. Hepatology (2010) 1.38
Drug-induced liver injury associated with stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. Hepatology (2015) 1.38
Isolation and culture of primary human hepatocytes. Methods Mol Biol (2005) 1.34
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology (2014) 1.31
Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther (2011) 1.28
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet (2014) 1.27
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos (2011) 1.22
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci (2010) 1.22
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today (2009) 1.16
Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol (2011) 1.14
Drug-induced liver injury with autoimmune features. Semin Liver Dis (2014) 1.09
The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther (2012) 1.06
Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf (2005) 1.05
Drug-induced acute liver failure. Clin Liver Dis (2013) 1.03
Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol (2007) 1.03
Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients. Expert Opin Drug Metab Toxicol (2014) 1.02
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol (2016) 1.01
The spectrum of hepatotoxicity. Perspect Biol Med (1968) 1.01
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int (2013) 1.00
Drug-induced acute liver failure. Eur J Gastroenterol Hepatol (2005) 1.00
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology (2014) 0.99
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer (2015) 0.99
Mechanisms of drug-induced liver injury. Clin Liver Dis (2013) 0.99
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today (2016) 0.98
Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther (2012) 0.95
Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem (2002) 0.95
Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf (2013) 0.94
A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers (2009) 0.94
Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. Toxicol Appl Pharmacol (2008) 0.94
Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology (2014) 0.93
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front Pharmacol (2014) 0.93
Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol Sci (2013) 0.92
Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf (2009) 0.91
Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol (2000) 0.90
Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. Gut (2016) 0.90
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest (2008) 0.90
Bile acids in drug induced liver injury: Key players and surrogate markers. Clin Res Hepatol Gastroenterol (2016) 0.89
Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol Sci (2014) 0.88
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol (2015) 0.88
High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos (2014) 0.87
Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res (2013) 0.86
Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity. J Pharmacol Exp Ther (2014) 0.86
Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf (2014) 0.86
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci (2016) 0.85
In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des (2010) 0.85
Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int (2015) 0.84
A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase. Toxicol Sci (2012) 0.84
Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol (2016) 0.84
Plasma glutathione S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage. Clin Chem (1989) 0.83
Drug-induced liver injury: the dawn of biomarkers? F1000Prime Rep (2015) 0.82
Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert Opin Drug Metab Toxicol (2014) 0.82
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. Int J Mol Sci (2016) 0.81
Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest (2012) 0.81
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. Pharmacogenomics J (2015) 0.80
Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing. Toxicol Sci (2015) 0.80
Minimizing DILI risk in drug discovery - A screening tool for drug candidates. Toxicol In Vitro (2015) 0.79
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics (2016) 0.79